ArticlePloS one2025
Multi-omics analysis of parthanatos related molecular subgroup and prognostic model development in stomach adenocarcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma.Mediators of inflammation · 2026Article
- Temporal transcriptomic atlas reveals sequential engagement of classical and emerging regulated cell death pathways during PRRSV infection.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stomach adenocarcinoma (STAD), the most prevalent histological subtype of gastric cancer, exhibits high heterogeneity and poor prognosis, posing significant therapeutic challenges. Parthanatos, a distinct form of regulated cell death mediated by poly (ADP-ribose) polymerase-1 (PARP-1), has been implicated in tumor biology and therapeutic resistance; however, the role of parthanatos-associated genes (PRGs) in STAD remains largely unexplored. In this study, we performed a comprehensive multi-omics analysis integrating transcriptomic, genomic, and clinical data from public databases to delineate the molecular landscape of PRGs in STAD. Unsupervised clustering revealed distinct PRG-related molecular subtypes with significant differences in clinical outcomes, immune infiltration profiles, and biological pathway activation. Based on machine learning algorithms, we established and validated a novel PRG-based prognostic signature, which demonstrated robust predictive performance. Moreover, single-cell RNA sequencing and in vitro functional assays were conducted to explore cellular heterogeneity and gene function. Notably, in vitro experiments, including western blot, colony formation, CCK-8, and Transwell assays, confirmed that one key PRG, COL8A1, promotes STAD cell proliferation and migration. Collectively, our findings highlight the clinical and biological significance of PRGs in STAD, offering novel biomarkers and potential therapeutic targets for STAD precision treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.